v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | EUCTR2020-002166-13-ES |
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002166-13/ES |
First author
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
|
Contact
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
rlleonart@bellvitgehospital.cat |
Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
2020-07-22 |
Recruitment status
Last imported at : March 31, 2022, 3:46 p.m. Source : EU Clinical Trials Register |
Completed |
Study design
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Randomized |
Design
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Open label |
Center
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Treatment |
Inclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
1-adult patients (18 years or older), both sexes 2-Sars-CoV-2 infection confirmed by PCR less than 4 days before randomization 3-hospitalized with a diagnosis of SARS-CoV-2 pneumonia 4-radiographic evidence of pulmonary infiltrates 5-grade 4 or 5 on the ordinal scale for the evaluation of the patient's clinical condition 6-pO2/FiO2 <380 7-men and women of childbearing age who have heterosexual relations must be agreement to use the safe method(s) of contraception 8-obtaining the informed consent of the patient or the legal representative. 1-pacientes adultos (18 años o más), de ambos sexos 2-infección por SARS-CoV-2 confirmada por PCR menos de 4 días antes de la aleatorización 3-hospitalizados con diagnóstico de neumonía por SARS-CoV-2 4-evidencia radiográfica de infiltrados pulmonares 5-grado 4 ó 5 en la escala ordinal para la evaluación del estado clínico del paciente 6-pO2/FiO2 <380 7-los hombres y mujeres en edad fértil que tienen relaciones heterosexuales deben estar de acuerdo en usar el método o métodos de anticoncepción seguros 8-obtención del consentimiento del paciente o representante legal. |
Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
1-imminent death (life expectancy less than 72h) 2-known hypersensitivity or known adverse reactions to the study drug, or its metabolites or excipients of the formulation 3-invasive mechanical ventilation 4-participation in any other clinical trial 5- ALT or AST > 5 x ULN 6-creatinine clearance <50 mL/min using the Cockcroft-Gault formula for participants '18 years old [Cockcroft 1976] 7-patients with recent acute coronary syndrome (<1 month) 8-patients with a history of stroke 9-positive pregnancy test 10-pregnant or lactating woman 1-muerte inminente (expectativa de vida menos de 72h) 2-hipersensibilidad conocida o reacciones adversas conocidas al fármaco del estudio, o a sus metabolitos o a excipientes de la formulación 3-ventilación mecánica invasiva 4-participación en cualquier otro ensayo clínico 5- ALT o AST > 5 x ULN 6-eliminación de creatinina <50 mL/min utilizando la fórmula Cockcroft-Gault para participantes `18 años de edad [Cockcroft 1976] 7-pacientes con síndrome coronario agudo reciente (< 1 mes) 8-pacientes con antecedentes de accidente cerebrovascular 9-prueba de embarazo positiva 10-mujer embarazada o lactante |
Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
2 |
Funding
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Dr. Ramón Lleonart Bellfill / Dr. Xavier Corbella Virós |
Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
100 |
Countries
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Spain |
Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Moderate/severe disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
4: Moderate/severe disease at enrollment |
Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
120 |
primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Efficacy and safety will be evaluated 10 (±1) days after the start of treatment or at hospital discharge if before day 10: number of patients reaching grade 2 (inpatient, no longer requiring supplemental oxygen and no longer requiring care or grade 1 (hospital discharge) of the ordinal scale of the clinical state of the patient for 48 hours straight* and who has not had an adverse reaction of 3 or 4 or 5 according to the Criteria of Adverse Event Terminology (CTC-AE of the term in Common Terminology Criteria for Adverse Events). La eficacia y seguridad se evaluará a los 10 (±1) días de haber iniciado el tratamiento o al alta hospitalaria si ésta ocurre antes del día 10: número de pacientes que alcanzan el grado 2 (paciente hospitalizado, que ya no requiere oxígeno suplementario y ya no requiere atención médica continua) o grado 1 (alta hospitalaria) de la escala ordinal del estado clínico del paciente durante 48 horas seguidas* y que no haya presentado una reacción adversa de grado 3 ó 4 ó 5 según los Criterios de Terminología de Eventos Adversos (CTC-AE del término en inglés Common Terminology Criteria for Adverse Events). |
Notes
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Declared number of arm (3.0) differs from found arms (2.0) |
Phase
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 7:26 a.m. Source : EU Clinical Trials Register |
[{"arm_notes": "", "treatment_id": 621, "treatment_name": "Icatibant", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |